53 Questions
What is the main difference in the duration of action between Salmeterol and Formoterol?
Salmeterol has a duration of action of 12 hours, while Formoterol has a duration of action of 7 hours
Which medication has a higher protein binding, leading to lower systemic side effects?
Salmeterol
Which combination of medications is reported to achieve the highest percentage of total control in asthma according to the concept study?
Seroflo (Salmeterol and Fluticasone propionate)
What is the maximum daily dose of Salmeterol?
160mcg
What is the main problem with the duration of action of Formoterol?
Too short, requiring more than twice daily use
Which medication is classified as a fast-acting bronchodilator?
Formoterol
Which medication is reported to achieve the highest percentage of total control in asthma according to the concept study?
Fluticasone propionate
Which of the following best describes the mechanism of action of Salmeterol?
Activation of intracellular adenyl cyclase leading to increased cAMP levels and bronchial smooth muscle relaxation
Which of the following is an advantage of Fluticasone Propionate over oral corticosteroids?
Low systemic side effects
What is the primary effect of Salmeterol on cytokine secretion?
Reduction of cytokine secretion
How does Fluticasone Propionate primarily contribute to the improvement in asthma and allergic responses?
Inhibition of inflammatory cells and secretion of histamines, cytokines, and leukotrienes
What is the onset of action for Salmeterol in Seroflo?
30 minutes
For which patient populations is Seroflo indicated?
Adults and adolescents
What is the primary mechanism of action for Fluticasone propionate in Seroflo?
Inhibiting inflammatory cells
In what forms are Seroflo and Symbicort available?
DPI and MDI
What percentage of the total market does the private sector represent?
78%
Which product leads the ICS/LABA combination market with 30% YOY 2022 growth in the private sector?
Budesonide/Formoterol
What is the total market size for the Combination ICS/LABA operating at 24% growth YOY 2022?
$2,819,055$ units
What is the main driver of growth in the total market for the Asthma ICS Combination market?
Private market
Which medication is gaining market share in both private and public sectors?
Bufomix
Which product is experiencing significant growth and gaining market share mainly driven by the public sector?
Airtec
Which medication is losing market share primarily in the public sector to Airtec?
Seretide
Which competitor is gaining market share from the SFP market in the private sector?
Combiwave
What is the maximum daily dose of Salmeterol?
120mcg
What is the main problem with the duration of action of Formoterol?
Short duration of action
Which medication is classified as a fast-acting bronchodilator?
Formoterol
What is the primary difference in protein binding between Salmeterol and Formoterol?
Salmeterol has higher protein binding
Which medication is reported to achieve the highest percentage of total control in asthma according to the concept study?
Fluticasone propionate
For which patient populations is Seroflo indicated?
Adult patients with asthma using ICS only
What is the percentage of the total market represented by the public sector?
22%
Which molecule leads the market with 30% YOY 2022 growth in the private sector for the ICS/LABA combination?
Budesonide/Formoterol
What is the main driver of growth for the Asthma ICS Combination market?
Private market
What is the growth rate for the MDI dosage form in the Asthma ICS Combination market in the private sector?
28%
Which product is the leading product in the Asthma Combination market?
Symbicort 160
What is the total market size for the Combination ICS/LABA operating at 24% growth YOY 2022?
2,819,055 units
What is the primary difference in the onset of action between Seroflo and Symbicort?
Seroflo has an onset of action of 30 minutes, while Symbicort has an onset of action of 15 minutes
In what patient populations is Seroflo indicated?
Asthma and COPD in adults and adolescents
What is the primary mechanism of action of Fluticasone propionate in Seroflo?
It has a glucocorticoid anti-inflammatory action within the lungs
Which medication may be used with a spacer device for patients who find it difficult to synchronize aerosol actuation with breath inspiration?
Seroflo
What is the duration of action for both Seroflo and Symbicort?
12 hours
What are the primary disadvantages of both Seroflo and Symbicort?
Oral infection, tremors, palpitation, and difficulty in usage
Which medication is losing market share by 14% in the public sector primarily to Airtec?
Seretide
Which product is gaining market share from the SFP (Seretide) market in the private sector?
BUD/FOR
What is the primary driver of Airtec's significant growth in the total asthma market?
Public sector demand
Which medication represents 17% of the total asthma market and is experiencing a 34% increase, mainly driven by the public market?
Airtec MDI
Which medication is gaining market share from Seretide MDI in the public sector and starting to gain market share from Seretide in the private sector?
Airtec-SF
Which medication is reported to achieve the highest percentage of total control in asthma according to the concept study?
Symbicort
Which of the following accurately describes the mechanism of action of Salmeterol?
Activation of intracellular adenyl cyclase, leading to increased cAMP levels and bronchial smooth muscle relaxation
Which of the following is a primary effect of Fluticasone Propionate in the context of asthma and allergic responses?
Inhibition of inflammatory cell activity and reduction of histamine, cytokine, and leukotriene secretion
What is the main advantage of Fluticasone Propionate over oral corticosteroids?
Low systemic side effects
How does Salmeterol primarily contribute to the improvement in COPD?
Reduction of cytokine secretion and improved mucociliary clearance
Which of the following accurately describes the mechanism of action of Salmeterol compared to salbutamol (albuterol)?
At least 50 times more selective for β2‐adrenoceptors
What is the primary action of increased cAMP levels due to the binding of Salmeterol to the β2‐adrenoceptor?
Bronchial smooth muscle relaxation
Study Notes
Pharmaceutical Market Analysis 2022
- The pharmaceutical market for bronchial asthma and chronic obstructive pulmonary disease (COPD) is growing at a rate of 30% year over year in both private (38% YOY) and public (21% YOY) sectors.
- Symbicort (AstraZeneca) is losing market share in both private (4% YOY) and public (11% YOY) sectors, while Bufomix (Hikma) is gaining market share, particularly in the private sector.
- Airtec is experiencing significant growth in both private and public sectors, gaining a 34% market share increase, mainly driven by the public sector.
- Seretide is losing market share by 14%, primarily in the public sector, to Airtec.
- The market share of SFP (seretide) is growing, while all other similar products are losing market share except for Seretide 125 (MDI) in the private sector and Seretide 250 (DPI) in the public sector.
- Airtec-SF (Combiwave) is gaining market share from Seretide (MDI) in the public sector and BUD/FOR is gaining market share from the SFP market in the private sector.
- Airtec MDI is gaining market share, representing 17% of the total asthma market and experiencing a 34% increase, mainly driven by the public market.
- Airtec is gaining market share from Seretide MDI in the public sector and starting to gain market share from Seretide in the private sector.
- The competitor landscape includes Symbicort, Seretide, Relvar Ellipta, Bufomix, Airtec-SF, and Flutiform, with various manufacturers and doses.
- The analysis includes a comparison of molecules in Symbicort, Seretide, Bufomix, Combiwave, and Formoterol, focusing on their uses and potential side effects.
- Detailed information is provided regarding the doses, manufacturers, and prices of different products such as Symbicort, Seretide, Bufomix, Airtec-SF, and Flutiform.
- The text provides a comprehensive understanding of the pharmaceutical market trends, including market growth, product performance, and competitor landscape in the bronchial asthma and COPD sector.
Pharmaceutical Market Analysis 2022
- The pharmaceutical market for bronchial asthma and chronic obstructive pulmonary disease (COPD) is growing at a rate of 30% year over year in both private (38% YOY) and public (21% YOY) sectors.
- Symbicort (AstraZeneca) is losing market share in both private (4% YOY) and public (11% YOY) sectors, while Bufomix (Hikma) is gaining market share, particularly in the private sector.
- Airtec is experiencing significant growth in both private and public sectors, gaining a 34% market share increase, mainly driven by the public sector.
- Seretide is losing market share by 14%, primarily in the public sector, to Airtec.
- The market share of SFP (seretide) is growing, while all other similar products are losing market share except for Seretide 125 (MDI) in the private sector and Seretide 250 (DPI) in the public sector.
- Airtec-SF (Combiwave) is gaining market share from Seretide (MDI) in the public sector and BUD/FOR is gaining market share from the SFP market in the private sector.
- Airtec MDI is gaining market share, representing 17% of the total asthma market and experiencing a 34% increase, mainly driven by the public market.
- Airtec is gaining market share from Seretide MDI in the public sector and starting to gain market share from Seretide in the private sector.
- The competitor landscape includes Symbicort, Seretide, Relvar Ellipta, Bufomix, Airtec-SF, and Flutiform, with various manufacturers and doses.
- The analysis includes a comparison of molecules in Symbicort, Seretide, Bufomix, Combiwave, and Formoterol, focusing on their uses and potential side effects.
- Detailed information is provided regarding the doses, manufacturers, and prices of different products such as Symbicort, Seretide, Bufomix, Airtec-SF, and Flutiform.
- The text provides a comprehensive understanding of the pharmaceutical market trends, including market growth, product performance, and competitor landscape in the bronchial asthma and COPD sector.
Test your knowledge of the pharmaceutical market landscape with this quiz. Explore the growth trends and market share between private and government sectors, and identify key molecules driving the growth. Brush up on your understanding of ICS, LABA, LAMA, Montelukast, and more.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
